Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 5 Aug 2022 Transparency notification FMR LLC Read More 5 Aug 2022 Disposal of own shares Read More 28 Jul 2022 Strong first six months – UCB with continued delivery and strong resilience Read More 20 Jul 2022 Acquisition and disposal of own shares Read More 15 Jul 2022 Acquisition and disposal of own shares Read More 9 Jul 2022 Acquisition and disposal of own shares Read More Pagination First page Previous page Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
